A new, retrospective study trying to tease out the benefits of MitraClip procedures according to the etiology of mitral regurgitation (MR) hints that, compared with conservative management, ...

January 6, 2012 (London, United Kingdom) — Results from the high-surgical-risk arm of the EVEREST II trial with the percutaneous MitraClip (Abbott) device, suggesting reduced mitral regurgitation and ...

August 28, 2011 (Paris, France) – The MitraClip (Abbott) percutaneous mitral-valve repair device may provide new hope for heart-failure patients who have otherwise run out of options [1]. A small ...

CHICAGO -- Emerging real-world data supported benefits of MitraClip therapy in patients with secondary mitral regurgitation (MR) who didn't fit the COAPT profile, the EXPAND study showed. MR was often ...

CHICAGO, IL—An analysis of patients treated with the MitraClip since its US approval in 2013 suggests that certain subtypes of both degenerative and functional mitral regurgitation (MR) may be ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with HF with moderate to severe or severe functional mitral regurgitation who underwent ...

Patients with secondary mitral regurgitation (MR) who were left with high gradients after a MitraClip procedure were not inherently at a disadvantage in their subsequent clinical outcomes, according ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter mitral valve repair improved clinical outcomes in patients with HF across all quartiles of mitral ...

Global health care major Abbott Laboratories ABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.

Ducharme is a contributor to TIME. A MitraClip surgery at one of the University of Colorado Hospital's catheter labs on Thursday, July 17, 2014 in Aurora, CO. Ducharme is a contributor to TIME. A ...

Abbott Lifesciences ABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy ...

The Ministry of Health Labour and Welfare ("MHLW") in Japan granted national reimbursement to Abbott 's ABT MitraClip therapy. The move is likely to improve the company's Structural Heart business.